NO962000D0 - Prolegemidler av en inhibitor av HIV-protease - Google Patents

Prolegemidler av en inhibitor av HIV-protease

Info

Publication number
NO962000D0
NO962000D0 NO962000A NO962000A NO962000D0 NO 962000 D0 NO962000 D0 NO 962000D0 NO 962000 A NO962000 A NO 962000A NO 962000 A NO962000 A NO 962000A NO 962000 D0 NO962000 D0 NO 962000D0
Authority
NO
Norway
Prior art keywords
promoters
protease inhibitor
hiv protease
hiv
inhibitor
Prior art date
Application number
NO962000A
Other languages
English (en)
Other versions
NO962000L (no
Inventor
Jose Alexander
Dilbir Bindra
Bruce D Dorsey
Arnold J Repta
Joseph P Vacca
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of NO962000D0 publication Critical patent/NO962000D0/no
Publication of NO962000L publication Critical patent/NO962000L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
NO962000A 1993-11-18 1996-05-15 Prolegemidler av en inhibitor av HIV-protease NO962000L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15420493A 1993-11-18 1993-11-18
PCT/US1994/013085 WO1995014016A1 (en) 1993-11-18 1994-11-14 Prodrugs of an inhibitor of hiv protease

Publications (2)

Publication Number Publication Date
NO962000D0 true NO962000D0 (no) 1996-05-15
NO962000L NO962000L (no) 1996-05-15

Family

ID=22550424

Family Applications (1)

Application Number Title Priority Date Filing Date
NO962000A NO962000L (no) 1993-11-18 1996-05-15 Prolegemidler av en inhibitor av HIV-protease

Country Status (17)

Country Link
US (1) US5733907A (no)
EP (1) EP0729467A1 (no)
JP (1) JPH09505303A (no)
KR (1) KR960705809A (no)
CN (1) CN1139432A (no)
AU (1) AU687128B2 (no)
CA (1) CA2174649A1 (no)
CZ (1) CZ140696A3 (no)
FI (1) FI962073L (no)
HU (1) HUT76270A (no)
IL (1) IL111584A0 (no)
NO (1) NO962000L (no)
NZ (1) NZ276622A (no)
PL (1) PL314486A1 (no)
SK (1) SK61496A3 (no)
WO (1) WO1995014016A1 (no)
ZA (1) ZA949127B (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458772B1 (en) 1909-10-07 2002-10-01 Medivir Ab Prodrugs
US6878728B1 (en) 1999-06-11 2005-04-12 Vertex Pharmaceutical Incorporated Inhibitors of aspartyl protease
US20040122000A1 (en) 1981-01-07 2004-06-24 Vertex Pharmaceuticals Incorporated. Inhibitors of aspartyl protease
MY126358A (en) * 1996-03-22 2006-09-29 Glaxo Group Ltd Compositions comprising vx478 and a water soluble tocopherol derivative such as vitamin e-tpgs
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
WO1999033795A1 (en) * 1997-12-24 1999-07-08 Vertex Pharmaceuticals Incorporated Prodrugs of aspartyl protease inhibitors
FR2773994B1 (fr) * 1998-01-23 2002-10-11 Univ Nice Sophia Antipolis Prodrogues issues d'anti-proteases inhibitrices du virus de l'immunodeficience humaine (vih) pour l'amelioration de leur biodisponibilite, de leur tropisme vers et/ou de leur delivrance dans le systeme nerveux central
AU767728B2 (en) 1998-06-19 2003-11-20 Vertex Pharmaceuticals Incorporated Sulfonamide inhibitors of aspartyl protease
US6319946B1 (en) 1999-02-12 2001-11-20 Vertex Pharmaceuticals Incorporated Inhibitors of aspartyl protease
CN1441790A (zh) * 2000-01-28 2003-09-10 罗姆和哈斯公司 增强性质的药物
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7202092B2 (en) * 2001-07-13 2007-04-10 Roche Diagnostics Operations, Inc. Indinavir derivatives useful in immunoassay
US6927036B2 (en) 2002-02-19 2005-08-09 Xero Port, Inc. Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
WO2005017106A2 (en) * 2003-06-17 2005-02-24 California Institute Of Technology Libraries of optimized cytochrome p450 enzymes and the optimized p450 enzymes
WO2005010011A2 (en) * 2003-07-15 2005-02-03 Xenoport, Inc. Methods of synthesis of acyloxyalkyl compounds
KR101140559B1 (ko) * 2003-08-20 2012-07-05 제노포트 인코포레이티드 아실옥시알킬 카르바메이트 프로드러그, 합성 및 사용 방법
CA2551859C (en) 2003-12-30 2011-10-04 Xenoport, Inc. Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US541168A (en) * 1895-06-18 Frank e
GB1338169A (en) * 1971-03-09 1973-11-21 Smith Kline French Lab Ureas thioureas and guanidines
US4144346A (en) * 1977-01-31 1979-03-13 Janssen Pharmaceutica N.V. Novel 1-(1,3-dioxolan-2-ylmethyl)-1H-imidazoles
US4661473A (en) * 1984-03-27 1987-04-28 Merck & Co., Inc. Renin inhibitors containing peptide isosteres
WO1989003842A1 (en) * 1987-10-21 1989-05-05 The Upjohn Company Renin inhibitors containing a (1-amino-2-hydroxy-2-heterocyclic) ethyl moiety
DK24089D0 (da) * 1989-01-20 1989-01-20 Hans Bundgaard Novel prodrug derivatives of biologically active agents containing hydroxyl groups or nh-acidic groups
US5218114A (en) * 1991-04-10 1993-06-08 Merck & Co., Inc. Cholecystokinin antagonists
US5169952A (en) * 1991-07-02 1992-12-08 Merck & Co., Inc. Stereoselective production of hydroxyamide compounds from chiral α-amino epoxides
US5413999A (en) * 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
CA2081970C (en) * 1991-11-08 1997-07-08 Joseph P. Vacca Hiv protease inhibitors useful for the treatment of aids
CZ293953B6 (cs) * 1993-07-16 2004-08-18 Mercká@Áco@Źáinc Způsob výroby meziproduktů pro výrobu inhibitorů HIV@proteázy a příslušné meziprodukty
US5463067A (en) * 1993-07-16 1995-10-31 Merck & Co., Inc. Process for making HIV protease inhibitors
WO1995010281A1 (en) * 1993-10-13 1995-04-20 Merck & Co., Inc. Combination therapy for hiv infection
US5455351A (en) * 1993-12-13 1995-10-03 Abbott Laboratories Retroviral protease inhibiting piperazine compounds

Also Published As

Publication number Publication date
NZ276622A (en) 1997-09-22
KR960705809A (ko) 1996-11-08
US5733907A (en) 1998-03-31
CN1139432A (zh) 1997-01-01
CA2174649A1 (en) 1995-05-26
EP0729467A1 (en) 1996-09-04
NO962000L (no) 1996-05-15
ZA949127B (en) 1996-05-17
FI962073A0 (fi) 1996-05-15
AU687128B2 (en) 1998-02-19
JPH09505303A (ja) 1997-05-27
PL314486A1 (en) 1996-09-16
HU9601340D0 (en) 1996-07-29
FI962073A7 (fi) 1996-05-15
HUT76270A (en) 1997-07-28
WO1995014016A1 (en) 1995-05-26
CZ140696A3 (en) 1996-12-11
SK61496A3 (en) 1996-11-06
IL111584A0 (en) 1995-01-24
AU1096095A (en) 1995-06-06
FI962073L (fi) 1996-05-15

Similar Documents

Publication Publication Date Title
NO303444B1 (no) Sulfonamidinhibitorer av HIV-aspartylprotease
DK0889036T3 (da) HIV-proteaseinhibitorer
NO962000D0 (no) Prolegemidler av en inhibitor av HIV-protease
FI20012317L (fi) Retrovirusproteaasi-inhibiittoreina käyttökelpoisia hydroksietyyliaminosulfoniamideja
FI950651L (fi) Retrovirusproteaasi-inhibiittoreina käyttökelpoisia sulfonyylialkanoyyliaminohydroksietyyliaminosulfoniamideja
PH31249A (en) Inhibitors of hiv protease.
FI20085256L (fi) Retrovirusperäisten proteaasi-inhibiittoreiden yhdistelmä
DE69509714D1 (de) Zerstörung von Unterwasser-Gegenständen
KR960701010A (ko) 사람 면역결핍 바이러스(HIV) 역전사효소의 억제제(Inhibitors of HIV reverse transcriptase)
FI962488L (fi) HIV:n proteaasin inhibiittoreita
NO934721D0 (no) Hemmere av HIV-protease som er nyttige for behandling av AIDS
NO934628D0 (no) Retrovirus-protease-inhibitorer
NO932130D0 (no) Hemmere av hiv-protease som er nyttige for behandling av aids
NO920025L (no) Synergime av hiv-reverstranskriptaseinhibitorer
NO953272L (no) Kombinasjoner av retrovirale inhibitorer
NO920023D0 (no) Hiv-proteaseinhibitorer
KR950011773U (ko) 신경제 기둥보의 형틀
FI970565L (fi) HIV-proteaasia inhiboiva yhdistelmä
SE9501324D0 (sv) Inhibitor of cellular immune response